

4-(4-methoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)-N-(2-methoxyethyl)benzamide;
N-((4-(1-((5-cyclopropyl-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)phenyl)sulfonyl)acetamide;
4-(6-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-6-azaspiro[2.5]octan-5-yl)benzoic acid;
4-ethyl-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
ethyl 4-((2S,4R)-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoate;
ethyl 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoate and salts, stereoisomers and tautomers thereof.

16. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and a therapeutically effective amount of a compound of any one of claims 1-15.

17. A combination, in particular a pharmaceutical combination, comprising a therapeutically effective amount of the compound according to any one of claims 1-15 and a second therapeutically active agent.

18. A compound according to any one of claims 1-15, for use as a medicament.

19. Use of a compound according to any one of claims 1-15, in the manufacture of a medicament for the treatment of age-related macular degeneration.

20. A compound of claim 1 which is 4-((4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid.